VITEK(R) 2 AST-P655, For susceptibility testing of Staphylococcus spp. Enterococcus spp., ad S agalactiae against specified antimicrobials, REF 421913 Product Usage: VITEK® 2 is an automated system consisting of instruments, software and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The VITEK® 2 utilizes growth-based biochemical patterns to determine identification. The VITEK® 2 provides minimal inhibitory concentration (MIC) results for most organism/drug combinations as well as a category interpretation (S, I, or R) consistent with accepted criteria.
Publicado el 26 de septiembre de 2018 · Inicio del retiro: 13 de agosto de 2018
Resumen
FDA registra el retiro Z-3180-2018 de dispositivos médicos de Clase II, publicado el 26 de septiembre de 2018 e iniciado el 13 de agosto de 2018. Empresa responsable: bioMerieux, Inc.; Estado: Finalizado; Cantidad reportada: 10919 cartons; Lote: Lot Numbers: 8050348103, 8050452403, 8050655403, 8050690403. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Routine internal review of Device History Records identified six VITEK(R) 2 AST card lots were manufactured with less drug (gentamicin) than required for the Gentamicin High-Level Resistance (ghlr01n) screen test due to an error when making 1500mL and 2000mL media well preparations (solutions).
Qué hacer
Voluntary: Firm initiated · E-Mail
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- bioMerieux, Inc.
- Distribuidor
- Worldwide Distribution US Nationwide and the countries of: Turkey, Austria, Switzerland, Czech Republic, Germany, Netherlands,
- Lote
- Lot Numbers: 8050348103, 8050452403, 8050655403, 8050690403
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAVITEK 2 Systems and VITEK 2 with MYLA.18 de mayo de 2022
- FDAVIDAS RUB IgG (RBG), REF 302265 de enero de 2022
- FDAVITEK® 2 Systems Software Version 9.01 Update Kit.26 de diciembre de 2018
- FDABACT/ALERT VIRTUO system, B Unit, with Version R2.0 Firmware Product Usage: The BacT/ALERT VIRTU Microbial31 de octubre de 2018
- FDAINFORM HPV III Fam 16 Probe - US Export, Catalog Number 05278856001, model 800-4295 Immunohistochemistry (IHC)26 de septiembre de 2018
- FDAURO-3 Triple Stain (CD44 + p53) with CK20, Catalog #: PM370TSAA, Package Type: Bag, which contains components:26 de septiembre de 2018
Preguntas sobre este retiro
¿VITEK(R) 2 AST-P655, For susceptibility testing of Staphylococcus spp. Enterococcus spp., ad S agalactiae against specified antimicrobials, REF 421913 Product Usage: VITEK® 2 is an automated system consisting of instruments, software and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The VITEK® 2 utilizes growth-based biochemical patterns to determine identification. The VITEK® 2 provides minimal inhibitory concentration (MIC) results for most organism/drug combinations as well as a category interpretation (S, I, or R) consistent with accepted criteria. fue retirado del mercado?
Sí. FDA publicó el retiro Z-3180-2018 el 26 de septiembre de 2018. Peligro reportado: Routine internal review of Device History Records identified six VITEK(R) 2 AST card lots were manufactured with less drug (gentamicin) than required for the Gentamicin High-Level Resistance (ghlr01n) screen test due to an error when making 1500mL and 2000mL media well preparations (solutions).
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · E-Mail